NCT06228924 - Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

October 1, 2029

Conditions

Arrhythmogenic Right Ventricular Cardiomyopathy

Interventions

GENETIC

TN-401

TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.

Trial Locations (7)

10016

RECRUITING

NYU Langone Health, New York

21287

RECRUITING

Johns Hopkins University, Baltimore

44195

RECRUITING

Cleveland Clinic, Cleveland

55905

RECRUITING

Mayo Clinic, Rochester

80045

RECRUITING

University of Colorado - Anschutz Medical Campus, Aurora

94143

RECRUITING

University of California San Francisco, San Francisco

02115

RECRUITING

Brigham and Women's Hospital, Boston